Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors

Gregory A. Masters, Bruce E. Brockstein, Sridhar Mani, Mark J. Ratain

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Docetaxel has demonstrated activity in a broad range of solid tumors. Phase I trials have shown 100 mg/m2 every 21 d to be the recommended dose. This phase I trial was designed to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of docetaxel with granulocyte colony-stimulating factor (G-CSF) support in patients with advanced solid tumors. Eligible patients had advanced malignancies and up to two prior chemotherapy regimens, ECOG PS = 0-1, adequate organ function, and gave written, informed consent. Docetaxel was escalated in cohorts of patients starting at 100 mg/m2 on a 21-d schedule. Prophylactic G-CSF was administered on d 3-10. The DLT was defined as grade IV neutropenia >4 d, febrile neutropenia, grade IV thrombocytopenia, any grade III non-hematologic toxicity, or the inability to receive cycle 2 because of ongoing toxicity. Twenty-three patients were enrolled at doses up to 145 mg/m2. The median age was 59 yr and the median number of prior chemotherapy regimens was 1. No DLT was observed at 100 mg/m2, and 2 of 11 patients at 120 mg/m2 experienced DLT (neutropenic fever and stomatitis). At 145 mg/m2, one of eight patients had DLT (fatigue). Two of eight patients at 145 mg/m2 had brief grade IV neutropenia (without fever), and none had grade III-IV thrombocytopenia or anemia. The docetaxel dose can be safely escalated to 145 mg/m2 every 21 d with G-CSF support, a 45% increase above the standard recommended phase II dose. Further studies will clarify the role of dose-intensified docetaxel.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalMedical Oncology
Volume20
Issue number1
DOIs
StatePublished - 2003

Fingerprint

docetaxel
Granulocyte Colony-Stimulating Factor
Neoplasms
Neutropenia
Thrombocytopenia
Fever
Drug Therapy
Febrile Neutropenia
Stomatitis
Maximum Tolerated Dose
Filgrastim
Informed Consent
Fatigue
Anemia
Appointments and Schedules

Keywords

  • Chemotherapy
  • Docetaxel
  • Dose escalation
  • Growth factor
  • Phase I

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors. / Masters, Gregory A.; Brockstein, Bruce E.; Mani, Sridhar; Ratain, Mark J.

In: Medical Oncology, Vol. 20, No. 1, 2003, p. 7-12.

Research output: Contribution to journalArticle

Masters, Gregory A. ; Brockstein, Bruce E. ; Mani, Sridhar ; Ratain, Mark J. / Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors. In: Medical Oncology. 2003 ; Vol. 20, No. 1. pp. 7-12.
@article{52ec024fb10c46a28615ddf5636cc0ef,
title = "Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors",
abstract = "Docetaxel has demonstrated activity in a broad range of solid tumors. Phase I trials have shown 100 mg/m2 every 21 d to be the recommended dose. This phase I trial was designed to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of docetaxel with granulocyte colony-stimulating factor (G-CSF) support in patients with advanced solid tumors. Eligible patients had advanced malignancies and up to two prior chemotherapy regimens, ECOG PS = 0-1, adequate organ function, and gave written, informed consent. Docetaxel was escalated in cohorts of patients starting at 100 mg/m2 on a 21-d schedule. Prophylactic G-CSF was administered on d 3-10. The DLT was defined as grade IV neutropenia >4 d, febrile neutropenia, grade IV thrombocytopenia, any grade III non-hematologic toxicity, or the inability to receive cycle 2 because of ongoing toxicity. Twenty-three patients were enrolled at doses up to 145 mg/m2. The median age was 59 yr and the median number of prior chemotherapy regimens was 1. No DLT was observed at 100 mg/m2, and 2 of 11 patients at 120 mg/m2 experienced DLT (neutropenic fever and stomatitis). At 145 mg/m2, one of eight patients had DLT (fatigue). Two of eight patients at 145 mg/m2 had brief grade IV neutropenia (without fever), and none had grade III-IV thrombocytopenia or anemia. The docetaxel dose can be safely escalated to 145 mg/m2 every 21 d with G-CSF support, a 45{\%} increase above the standard recommended phase II dose. Further studies will clarify the role of dose-intensified docetaxel.",
keywords = "Chemotherapy, Docetaxel, Dose escalation, Growth factor, Phase I",
author = "Masters, {Gregory A.} and Brockstein, {Bruce E.} and Sridhar Mani and Ratain, {Mark J.}",
year = "2003",
doi = "10.1385/MO:20:1:7",
language = "English (US)",
volume = "20",
pages = "7--12",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors

AU - Masters, Gregory A.

AU - Brockstein, Bruce E.

AU - Mani, Sridhar

AU - Ratain, Mark J.

PY - 2003

Y1 - 2003

N2 - Docetaxel has demonstrated activity in a broad range of solid tumors. Phase I trials have shown 100 mg/m2 every 21 d to be the recommended dose. This phase I trial was designed to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of docetaxel with granulocyte colony-stimulating factor (G-CSF) support in patients with advanced solid tumors. Eligible patients had advanced malignancies and up to two prior chemotherapy regimens, ECOG PS = 0-1, adequate organ function, and gave written, informed consent. Docetaxel was escalated in cohorts of patients starting at 100 mg/m2 on a 21-d schedule. Prophylactic G-CSF was administered on d 3-10. The DLT was defined as grade IV neutropenia >4 d, febrile neutropenia, grade IV thrombocytopenia, any grade III non-hematologic toxicity, or the inability to receive cycle 2 because of ongoing toxicity. Twenty-three patients were enrolled at doses up to 145 mg/m2. The median age was 59 yr and the median number of prior chemotherapy regimens was 1. No DLT was observed at 100 mg/m2, and 2 of 11 patients at 120 mg/m2 experienced DLT (neutropenic fever and stomatitis). At 145 mg/m2, one of eight patients had DLT (fatigue). Two of eight patients at 145 mg/m2 had brief grade IV neutropenia (without fever), and none had grade III-IV thrombocytopenia or anemia. The docetaxel dose can be safely escalated to 145 mg/m2 every 21 d with G-CSF support, a 45% increase above the standard recommended phase II dose. Further studies will clarify the role of dose-intensified docetaxel.

AB - Docetaxel has demonstrated activity in a broad range of solid tumors. Phase I trials have shown 100 mg/m2 every 21 d to be the recommended dose. This phase I trial was designed to define the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of docetaxel with granulocyte colony-stimulating factor (G-CSF) support in patients with advanced solid tumors. Eligible patients had advanced malignancies and up to two prior chemotherapy regimens, ECOG PS = 0-1, adequate organ function, and gave written, informed consent. Docetaxel was escalated in cohorts of patients starting at 100 mg/m2 on a 21-d schedule. Prophylactic G-CSF was administered on d 3-10. The DLT was defined as grade IV neutropenia >4 d, febrile neutropenia, grade IV thrombocytopenia, any grade III non-hematologic toxicity, or the inability to receive cycle 2 because of ongoing toxicity. Twenty-three patients were enrolled at doses up to 145 mg/m2. The median age was 59 yr and the median number of prior chemotherapy regimens was 1. No DLT was observed at 100 mg/m2, and 2 of 11 patients at 120 mg/m2 experienced DLT (neutropenic fever and stomatitis). At 145 mg/m2, one of eight patients had DLT (fatigue). Two of eight patients at 145 mg/m2 had brief grade IV neutropenia (without fever), and none had grade III-IV thrombocytopenia or anemia. The docetaxel dose can be safely escalated to 145 mg/m2 every 21 d with G-CSF support, a 45% increase above the standard recommended phase II dose. Further studies will clarify the role of dose-intensified docetaxel.

KW - Chemotherapy

KW - Docetaxel

KW - Dose escalation

KW - Growth factor

KW - Phase I

UR - http://www.scopus.com/inward/record.url?scp=0037233591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037233591&partnerID=8YFLogxK

U2 - 10.1385/MO:20:1:7

DO - 10.1385/MO:20:1:7

M3 - Article

C2 - 12665678

AN - SCOPUS:0037233591

VL - 20

SP - 7

EP - 12

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 0340-7004

IS - 1

ER -